News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Mural Oncology plc (NASDAQ: MURA) had its price target lowered by analysts at HC Wainwright from $18.00 to $6.00. They now have a "buy" rating on the stock.

Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.

Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Raymond James from a "strong-buy" rating to an "outperform" rating. They now have a $18.00 price target on the stock.

Mural Oncology plc (NASDAQ: MURA) had its "hold" rating re-affirmed by analysts at Jones Trading.

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

Form 8-K Mural Oncology plc For: Mar 25

Form 8-K Mural Oncology plc For: Mar 11

Form 424B5 Mural Oncology plc

Form S-8 Mural Oncology plc

Form 10-K Mural Oncology plc For: Dec 31

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}